Highlights

  • Amplia Therapeutics Ltd (ASX: ATX) traded at $0.155 as at 3:00pm AEST on August 7, 2026.
  • The stock recorded an increase of approximately 3.33 percent for the session based on the data reviewed.
  • Shares traded within an intraday range of $0.145 to $0.155.
  • Market capitalisation stood at approximately $79.56 million.
  • Trading volume reached 842,471 shares during the session.

Amplia Therapeutics Ltd (ASX: ATX) shares were trading at $0.155 as at 3:00pm AEST on August 7, 2026, after recording an increase of approximately 3.33 percent during the session. The stock traded within an intraday range of $0.145 to $0.155, while the broader S&P/ASX 200 Health Care Index moved lower during the same period.

Amplia Therapeutics Share Price Movement on August 7, 2026

The data reviewed showed that Amplia Therapeutics shares recorded an increase of approximately 3.33 percent for the session. The stock traded between an intraday low of $0.145 and a high of $0.155.

The movement reflected activity within the company’s daily trading range. Share price movements for biotechnology companies can vary due to company-specific developments, market participation, sector sentiment and broader market conditions.

Trading Volume and Market Capitalisation

Trading volume for Amplia Therapeutics reached 842,471 shares during the session. Based on the reported share price, the company’s market capitalisation stood at approximately $79.56 million.

The trading volume reflected participation in the stock during the reviewed period, while the market capitalisation placed Amplia Therapeutics among the smaller-capitalisation companies within the ASX health care sector.

One-Year Share Price Performance

Over the trailing one-year period, Amplia Therapeutics recorded a decline of approximately 16.22 percent based on the data reviewed.

Biotechnology companies can experience share price movements influenced by company-specific developments, research and development activities, clinical progress, sector sentiment and broader market conditions.

ASX Health Care Sector Performance

The broader S&P/ASX 200 Health Care Index (XHJ) was trading at 28,010.8 points, down 224.7 points or 0.80 percent, as at 3:20pm AEST on August 7, 2026, with the market session still open.

The index traded within an intraday range of 27,808.8 to 28,235.5 points against a previous close of 28,235.5. Over the past 52 weeks, the index ranged between 21,947.2 and 45,579.6 points, with a one-year return of negative 37.37 percent.

Individual health care companies can record movements that differ from the broader index due to company-specific factors, trading volumes and investor participation.

About Amplia Therapeutics Ltd

Amplia Therapeutics Ltd is an Australian clinical-stage biotechnology company listed on the ASX under the ticker code ATX and classified within the health care sector.

Companies operating within biotechnology can experience share price activity influenced by research developments, market expectations, sector conditions and broader investor sentiment.

Understanding the Trading Data

The share price, trading volume and market capitalisation figures provide an overview of Amplia Therapeutics’ market activity during the reviewed session.

Trading volume represents the number of shares exchanged during the period, while market capitalisation reflects the market value based on the reported share price and shares on issue. A single trading session provides a snapshot of market activity and does not necessarily represent a longer-term trend.

Conclusion

As at 3:00pm AEST on August 7, 2026, Amplia Therapeutics Ltd (ASX: ATX) shares were trading at $0.155, within a day range of $0.145 to $0.155, on trading volume of 842,471 shares and a market capitalisation of approximately $79.56 million.

The stock recorded an increase of approximately 3.33 percent during the session, while the broader S&P/ASX 200 Health Care Index traded lower. Over the trailing one-year period, Amplia Therapeutics recorded a decline of approximately 16.22 percent based on the data reviewed.